| Popis: |
Malaria is a major threat to the public health and economic development of many nations. While P. falciparum causes most malaria-induced mortality worldwide, P. vivax is the major cause of malaria morbidity. In this study we have compared two different brands of Arteether (EMAL and MATCH) for treating P. vivax initially. Arteether™ is a useful drug against chloroquine-resistant P. vivax malaria, without an increased incidence of toxicity. It has a longer half-life and has more lipophilic properties than artemether™, which aids its accumulation in brain tissues for the treatment of cerebral malaria. The study revealed that there was a significant difference in the effectiveness of these two formulations even though they were labeled to have similar indications. These indicate the need for prior examination of these kinds of products for their intended activity. The results of this study have provided evidence to support the better effectiveness of EMAL- brand over MATCH- brand. As EMAL has less viscosity, very good redispersibility, larger zone of inhibition. By observing all of these properties we can conclude that EMAL is a better formulation than MATCH, and can show better antimalarial property in patient suffering from Plasmodium malaria. Keywords: Antimalarial, Plasmodium species, Zone of inhibition, Indications, Mortality, Half-life |
